CELL INTELLIGENCE · 肿瘤细胞治疗研究

FOXP1 敲低重编程 Th9 CAR-T 细胞以克服抗原逃逸

FOXP1 Knockdown Reprograms Th9 CAR-T Cells to Overcome Antigen Escape.

体内全基因组 CRISPR 筛选鉴定 FOXR1 为 CD8(+) T 细胞抗肿瘤免疫的抑制因子

In vivo genome-wide CRISPR screens identify FOXR1 as a suppressor of CD8(+) T cell antitumor immunity.

体内 CAR-T 用于实体瘤：面临体外 CAR-T 的所有挑战及更多

In vivo CAR-T for solid tumors: facing all the challenges of ex vivo CAR-T and more.

儿童实体瘤的嵌合抗原受体（CAR）-T 细胞疗法：当前突破、困境与策略

Chimeric antigen receptor (CAR)-T cell therapy for solid tumors in pediatric patients: current breakthroughs, dilemmas, and strategies.

体内 CAR-T 细胞生成：递送平台、临床进展与转化障碍

In vivo CAR T-cell generation: delivery platforms, clinical progress, and translational barriers.

镁功能化水凝胶递送 CAR-T 细胞增强腹膜转移治疗

Delivery of CAR T Cells in a Magnesium-Functionated Hydrogel Boosts Peritoneal Metastasis Treatment.

免疫功能低下宿主中耐药革兰阴性感染的新型抗生素：从关键试验到高风险实践

Newer antibiotics for drug-resistant Gram-negative infections in immunocompromised hosts: from pivotal trials to high-risk practice.

更正：靶向膜结合 HSP70 的颗粒酶 B 型 CAR-T 细胞抑制实体瘤生长与转移

Correction: Granzyme B-based CAR-T cells targeting membrane-bound HSP70 suppress solid tumor growth and metastasis.

CLDN18.2 阳性肿瘤的耐药机制与应对策略：从分子网络到临床实践

Resistance mechanisms and countermeasures in CLDN18.2-positive tumors: from molecular networks to clinical practice.

治疗前 TyG-BMI 预测弥漫大 B 细胞淋巴瘤中 CD19 CAR-T 的持久性与预后

Pretreatment TyG-BMI predicts CD19 CAR-T persistence and prognosis in diffuse large B-cell lymphoma.

TyG-BMI 是 DLBCL 的独立预后因素，可细化基于 IPI 的分层，并且输注前 TyG-BMI 升高与 CAR-T 细胞持久性减弱和较差结局相关。这一易于获取的代谢指标可能有助于 DLBCL 的风险评估和治疗规划。